Market Overview

Merck, AstraZeneca Announce License Agreement for MK-1775

Related MRK
Merck Has An Upcoming PDUFA Date For Bezlotoxumab
Are The Drugs Working? Pharma Giants Eli Lilly And Merck To Update Investors On Cancer Treatments
Here's How Lilly And Merck Are Faring In The Cancer Drug Wars: Earnings Out Next Week (Seeking Alpha)

Merck (NYSE: MRK), known as MSD outside the United States and Canada,
and AstraZeneca (NYSE: AZN) today announced a worldwide licensing
agreement for Merck's oral small molecule inhibitor of WEE1 kinase
(MK-1775). MK-1775 is currently being evaluated in Phase IIa clinical
studies in combination with standard-of-care therapies for the treatment
of patients with certain types of ovarian cancer.

WEE1 helps to regulate the cell-division cycle. The WEE1 inhibitor
MK-1775 is designed to cause certain tumor cells to divide without
undergoing normal DNA repair processes, ultimately leading to cell
death. Preclinical evidence suggests that the combination of MK-1775 and
DNA damage-inducing chemotherapy agents can enhance anti-tumor
properties, in comparison to chemotherapy alone.

See full press release

Posted-In: News Guidance Contracts Management Global


Related Articles (AZN + MRK)

View Comments and Join the Discussion!